From: The impact of Cysteine-Rich Intestinal Protein 1 (CRIP1) in human breast cancer
CRIP1 | ||||
 | negative (0) | 36 | 21 / 58% |  |
 | positive (1+, 2+, 3+) | 75 | 28 / 37% | p = 0.039 |
CRIP1 in lymph node-negative tumors | ||||
 | CRIP1 negative (0) | 23 | 11 / 48% |  |
 | CRIP1 positive (1+, 2+, 3+) | 44 | 11 / 25% | p = 0.1 n.s. |
CRIP1 in lymph node-positive tumors | ||||
 | CRIP1 negative (0) | 13 | 10 / 77% |  |
 | CRIP1 positive (1+, 2+, 3+) | 33 | 17 / 52% | p = 0.09 n.s. |
CRIP1 in HER2-negative tumors (0) | ||||
 | CRIP1 negative (0) | 14 | 7 / 50% |  |
 | CRIP1 positive (1+, 2+, 3+) | 14 | 5 / 36% | p = 0.6 n.s. |
CRIP1 in HER2-positive tumors (1+, 2+, 3+) | ||||
 | CRIP1 negative (0) | 21 | 14 / 67% |  |
 | CRIP1 positive (1+, 2+, 3+) | 59 | 23 / 39% | p = 0.021 |
Multivariate Cox regression analysis | ||||
 | coefficient | chi2 | p-value |  |
nodal status | 0.86 | 7.45 | 0.006 | Â |
tumor size | 0.51 | 4.58 | 0.03 | Â |
CRIP1 | −0.66 | 4.28 | 0.039 * | total p = 0.029 |